When you stop tesamorelin, the belly fat it removed, the deep visceral fat around your organs, typically comes back over the following months. The trials show this clearly. What decides how much comes back, and how fast, is whatever was feeding that fat in the first place.
This page settles what the published tesamorelin trials actually measured after people came off it, why the visceral fat returned, and what research suggests has to be in place before stopping for more of the loss to hold. It is written for anyone running tesamorelin for belly fat, or thinking about it, who wants to know what happens at the end of the protocol before getting there.
What happens when you stop tesamorelin: what the trials measured
Visceral fat is the deep fat packed around your organs, behind the muscle wall of the stomach. It is not the fat you can pinch. It is the fat that pushes the stomach out from the inside, and it is the fat research ties most closely to insulin problems and heart risk. That is the fat tesamorelin was developed to reduce, and it is the only fat the trials measured as their main result.
The largest tesamorelin trials were two phase 3 studies in adults with HIV who had built up excess visceral fat on their antiretroviral medication. That population matters for how far the results can be stretched, and it comes up again in the FAQ. Both trials ran the same way. For the first 26 weeks, one group got tesamorelin and one group got a placebo, and visceral fat was measured on a CT scan, an imaging scan that can separate deep fat from the fat under the skin.
The first 26 weeks
The tesamorelin groups lost visceral fat. The first trial reported a drop of about 15 percent, while the placebo group drifted up about 5 percent. The second trial reported a smaller drop of about 11 percent against a placebo group that barely moved. Pooled across both studies, the reduction lands somewhere around 15 to 18 percent, depending on whether it is measured at 26 or 52 weeks. Limb fat and the fat under the skin of the abdomen did not change much, which is why tesamorelin is described as selective for the deep fat.
The switch at week 26
At week 26 the researchers did something that answers the stopping question directly. They took the people already on tesamorelin and randomly split them. Some kept going. The rest were switched to placebo without being told. Everyone kept getting scanned for another 26 weeks. Same people, same scanner, same measurement. The only thing that changed for the switched group was that the compound stopped.
| Group (first trial) | Baseline scan | Week 26 scan | Week 52 scan |
|---|---|---|---|
| Stayed on tesamorelin | Starting point | About 18% less visceral fat than baseline | Reduction held at about 18%, no further loss |
| Switched to placebo at week 26 | Starting point | Same loss as the group that stayed on | Net loss of only about 1.6% from baseline |
| Placebo first, then started tesamorelin | Starting point | Drifted up slightly | About 12.5% lost in the 26 weeks after starting |
The group that came off gave back nearly all of what they had lost. Waist measurements told the same story: in the switched group, a 2 centimeter waist reduction at week 26 had shrunk to about 1 centimeter by week 52. The trial authors described the visceral fat improvements as rapidly lost after the switch. Growth hormone markers followed the same path, with IGF-1 (the growth factor your liver makes in response to growth hormone) staying up in the people who continued and returning to baseline in the people who stopped.
One honest limit on the table: the scans were taken at baseline, week 26, and week 52. Nobody was scanned week by week in between, so the exact pace of regain inside those 26 weeks is not in the published data. What the data does show is the direction and the end point. Based on the trials, stopping tesamorelin means the visceral fat typically returns over several months. Not overnight, but it returns.
If the question in your head right now is whether your own visceral fat will come back once you stop tesamorelin, ask it here and the first answer shows in full for free.
Why visceral fat returns after tesamorelin stops
Tesamorelin is a GHRH analog, meaning a lab-made copy of the signal your brain sends to release growth hormone. It tells your pituitary, the small gland at the base of the brain, to put out more of your own growth hormone. It does not add growth hormone from outside the body. It gets your own supply moving harder, which is the core difference covered in HGH vs tesamorelin, replacement versus optimization.
Growth hormone is one of the few signals in the body that tells fat cells to open up and release what they are storing, a process called lipolysis, meaning fat breakdown. Visceral fat seems to respond to that signal more strongly than the fat under the skin does, which fits the trial pattern of deep fat dropping while limb and surface fat barely moved. That is why tesamorelin pulls from the visceral fat first.
The sump pump
The clearest way to picture it is a sump pump in a basement. Tesamorelin is the pump. While it runs, it pulls water out faster than water comes in, and the basement looks dry. But the water is still seeping in from the ground around the house, because nothing about the ground has changed. Shut the pump off and the basement fills back up.
That is what the week 52 scans showed. The pump was doing the work the whole time, and the inflow never stopped. Tesamorelin has a short half life, meaning it clears from the body quickly, so once injections end the extra growth hormone signal fades within days and IGF-1 drifts back to where it started. The pull is gone. Whatever was feeding the visceral fat before the protocol is still feeding it after.
So the useful question is not whether the pump works. It clearly does. The useful question is what is letting the water in.
The four inputs that keep refilling visceral fat
Visceral fat rarely has one cause. In most people several inputs are feeding it at the same time, and tesamorelin does not directly fix any of them. It drains the fat while they keep adding to it. The same inputs explain why tesamorelin sometimes does not seem to touch belly fat at all, even while it is running.
| Input | What it does to visceral fat | How it is measured |
|---|---|---|
| Short or poor sleep | Raises cortisol, the main stress hormone. Research suggests cortisol tends to steer fat storage toward the visceral area. | Average hours per night over a few weeks; morning cortisol if testing |
| Low insulin sensitivity | Cells respond less to insulin, so insulin runs higher and longer. That pattern is closely tied to visceral fat building up. | Fasting insulin, fasting glucose, HbA1c (a three month blood sugar average), triglycerides |
| Not enough muscle | Muscle is one of the main places incoming food gets stored and burned. Less of it leaves more to be stored as fat. | Consistent resistance training per week; strength trend; body composition if available |
| Diet heavy in processed food | Keeps insulin elevated for much of the day, which feeds the same pattern as low insulin sensitivity. | What a normal week of eating actually looks like, written down |
Muscle is the input people underrate most. Keeping lean tissue while fat comes down is its own problem, and the Lean Mass Protection research guide covers what the research shows on holding it. The point here is narrower: every pound of working muscle is somewhere food goes instead of the visceral fat.
None of these are visible from the outside, and two of them only show up in blood. That is why guessing at which one is driving it for you tends to go wrong.
Two researchers, the same six months, different results
The first researcher runs tesamorelin for six months and watches his waist come down. Then he stops. Nothing else changed during those six months. He is still sleeping five or six hours a night and training whenever he gets around to it. Six months after stopping, his waist is back where it started, and he decides the compound did not work. It did work. He shut the pump off with the water still coming in.
The second researcher runs the same six months, but while the pump is running he works on the inflow. He gets his sleep up. He lifts consistently, three days a week, every week. He moves his insulin sensitivity in the right direction, usually by cutting most processed food and walking after meals. When he stops, some visceral fat typically still comes back, because the growth hormone signal is gone. But based on how visceral fat behaves, less of it comes back, and it comes back slower, because less is feeding it.
Same compound, same six months, two different outcomes. The trials did not test lifestyle changes during the protocol, so this comparison is built from what is known about each input, not from a head to head study. But it lines up with the one thing the trials made clear: the compound does not change what refills the fat. The researcher who treats tesamorelin as the fix is the researcher who ends up paying for the same visceral fat twice.
Whether visceral fat comes back after tesamorelin depends on inputs you cannot feel, like fasting insulin, blood sugar, and cortisol. This tool takes your age, goal, and symptoms and returns the panel to bring to your doctor, ranked by which system your symptoms point to. Three minutes now versus finding out from your waistband six months after stopping.
Show Me My PanelFree. No login. Takes about three minutes.
How to tell if belly fat is coming back after you stop tesamorelin
The scale is the wrong tool for this. Visceral fat can come back while body weight barely moves, because some muscle can be lost at the same time and the two cancel out on the scale. The trials measured with CT scans for a reason.
The waist measurement
Measure your waist at the belly button, at the same time of day, once a week, starting before you stop so there is a real baseline instead of a feeling. A tape measure is a rough stand in for a CT scan, but it moved in the same direction in the trials. If that number climbs two or three weeks in a row after stopping, visceral fat is the likely reason. A related pattern worth noticing is the waistband getting tighter while the thighs fit the same, since visceral fat sits only in the trunk while fat under the skin tends to spread more widely. It is a clue, not a diagnosis, because where surface fat lands varies from person to person.
The blood markers
Visceral fat and blood sugar control tend to move together. Fasting glucose is the marker most people can check, but it is often the last one to move. Fasting insulin, HbA1c, and triglycerides usually shift earlier, which makes them more useful for catching the trend while it is still small. Energy after meals is a softer signal: crashing an hour after eating often points to insulin sensitivity slipping, and that tends to travel with visceral fat.
What to have in place before stopping tesamorelin
Once you know what is letting the water in, the decision gets simpler. The order below follows what is most often off and what the other inputs depend on. It is a research framework, not a prescription.
| If this is true | What the research points to |
|---|---|
| Sleep is under six hours most nights | The first input to work on, because short sleep pushes cortisol and insulin in the wrong direction at the same time. |
| Lifting fewer than two or three days a week | Building consistency here, because muscle is where food goes instead of into visceral fat. |
| Fasting insulin, glucose, HbA1c, or triglycerides trending up | An insulin sensitivity problem, one of the inputs most closely tied to visceral fat. Processed food and post-meal walking are the usual first levers. |
| All three already handled | The best position to stop from. The pump did its job and the ground around the house is drier than it was. |
How long to run tesamorelin and how to come off it is a separate question, covered in how long to run retatrutide and tesamorelin and whether to cycle off. This page is about what holds the result once you do.
Tesamorelin buys you time
The trials are clear that stopping tesamorelin typically brings visceral fat back over the following months, because the compound drains the fat without changing what feeds it. How much returns depends on sleep, insulin sensitivity, muscle, and diet during the protocol. Tesamorelin buys you time. What you do with that time is what you get to keep.
Stopping tesamorelin: common questions
The data does not suggest it. Tesamorelin works through your own pituitary rather than replacing growth hormone from outside, so there is no shutdown of your own production the way there can be with outside growth hormone. In the trials, IGF-1 returned to baseline after stopping rather than dropping below it, and the switched group's visceral fat came back toward its starting level, not past it.
That is the biggest open question. The large stopping data comes from adults with HIV whose visceral fat built up on their medication, and the label approval is for that group. The mechanism, a stronger growth hormone pulse acting on fat cells, is not specific to HIV, so a similar pattern is plausible in other people, but there is no large controlled stopping trial outside that population to confirm the size of the effect.
No. The trials defined a responder as someone whose visceral fat dropped at least 8 percent, and roughly 69 percent of people met that bar at 26 weeks. A follow-up analysis found that responders tended to see better triglycerides with blood sugar control mostly unchanged, while non-responders tended to see blood sugar control get slightly worse. That is one more reason a baseline panel before starting is useful.
There is no trial that stopped people and then restarted them. The closest data is the group that started on placebo and switched to tesamorelin at week 26, which lost about 12.5 percent in the next 26 weeks, so starting later did not seem to blunt the response. Whether a second run after a break behaves the same way has not been directly studied.
The hormone signal is gone within days. IGF-1 was back at baseline by the next scan in the trial group that stopped. The belly fat is slower. In the trial, people who stopped at week 26 had given back nearly all of their visceral fat loss by week 52, so the honest window is a few months, not a few weeks, and the pace inside that window depends on what is feeding the fat underneath.
Not in the trial data. The group that stayed on for 52 weeks held its reduction at about 18 percent but did not lose much more after week 26, which the researchers read as a plateau at the trial dose. The second six months mostly protected the first six months rather than adding to them.
If you still have a question this page did not settle, something like whether tesamorelin results hold for someone without HIV, type it into the Research Engine and the first answer shows in full for free.
For educational and research purposes only. Not medical advice. Project Theo does not provide dosing recommendations or sourcing information.